Leerink Partnrs Predicts Oculis’ Q2 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Investment analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of Oculis in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($0.50) per share for the quarter, down from their prior forecast of ($0.48). The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. Leerink Partnrs also issued estimates for Oculis’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($3.49) EPS, FY2028 earnings at ($2.20) EPS and FY2029 earnings at $0.43 EPS.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

A number of other brokerages have also recently issued reports on OCS. Robert W. Baird increased their price objective on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. HC Wainwright increased their price objective on Oculis from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, April 17th. Finally, Chardan Capital increased their price objective on Oculis from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, May 9th.

Oculis Stock Down 0.7%

OCS stock opened at $19.79 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The company has a market capitalization of $864.07 million, a price-to-earnings ratio of -10.25 and a beta of 0.35. Oculis has a fifty-two week low of $10.79 and a fifty-two week high of $23.08. The stock has a fifty day moving average of $17.99 and a 200-day moving average of $18.80.

Hedge Funds Weigh In On Oculis

A number of large investors have recently modified their holdings of OCS. Bellevue Group AG purchased a new position in shares of Oculis during the 4th quarter valued at about $170,000. XTX Topco Ltd purchased a new position in shares of Oculis during the 4th quarter valued at about $225,000. Kestra Private Wealth Services LLC purchased a new position in shares of Oculis during the 1st quarter valued at about $234,000. Geode Capital Management LLC raised its holdings in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after buying an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Oculis during the 4th quarter valued at about $389,000. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.